Evidence supporting the use of: Phytocannabinoid (unspecified)
For the health condition: Addictions (general remedies for)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Phytocannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), have been studied for their potential roles in treating addiction. The most research to date focuses on CBD, a non-psychoactive cannabinoid found in cannabis. Preclinical studies in animal models and some early-phase human trials suggest CBD may help reduce drug-seeking behavior and withdrawal symptoms associated with substances such as opioids, cocaine, tobacco, and alcohol. Proposed mechanisms include modulation of the endocannabinoid system, reduction of anxiety and stress, and neuroprotective effects.

For example, a 2019 randomized controlled trial (Hurd et al., American Journal of Psychiatry) found that CBD reduced cue-induced craving and anxiety in individuals with heroin use disorder. Other studies have evaluated CBD for smoking cessation and alcohol use disorder, but results are preliminary and sometimes inconsistent. THC and whole-plant cannabis have also been explored, particularly in harm reduction approaches, but evidence is weaker and complicated by potential for abuse.

Overall, while there is growing scientific interest and some promising early findings, the clinical evidence is currently limited, with small sample sizes and short study durations. Larger and more rigorous studies are needed before phytocannabinoids can be widely recommended for addiction treatment. Thus, the evidence is rated as 2/5, indicating early scientific support but not yet strong validation.

More about Phytocannabinoid (unspecified)
More about Addictions (general remedies for)

Products containing Phytocannabinoid (unspecified)

We currently have no products on Vitabase that contain this ingredient.